Teva Pharmaceutical TEVA today announced data
from the Phase III Glatiramer Acetate Low-Frequency Administration
(GALA) study. The GALA study was designed to evaluate the efficacy,
safety and tolerability of an investigational dosing regimen of
glatiramer acetate (GA), the therapeutic agent in COPAXONE®
(glatiramer acetate injection), which is indicated for the treatment of
relapsing-remitting multiple sclerosis (RRMS). Detailed study results
will be presented at the 28th Congress of the European
Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in
Lyon, France during the late-breaking news parallel session on October
13, 2012.
“We are excited about the potential to offer RRMS patients another safe
and effective treatment option
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in